{"id":"fesoterodine-pr","safety":{"commonSideEffects":[{"rate":"35-40","effect":"Dry mouth"},{"rate":"15-20","effect":"Constipation"},{"rate":"5-10","effect":"Headache"},{"rate":"5-8","effect":"Urinary tract infection"},{"rate":"3-5","effect":"Blurred vision"}]},"_chembl":{"chemblId":"CHEMBL1201764","moleculeType":"Small molecule","molecularWeight":"411.59"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fesoterodine is a prodrug that is rapidly hydrolyzed to its active metabolite, which selectively blocks M3 muscarinic acetylcholine receptors on bladder detrusor muscle. This antagonism prevents acetylcholine-induced bladder contractions, increasing bladder capacity and reducing the urge to urinate. The extended-release (PR) formulation provides sustained drug delivery for once-daily dosing.","oneSentence":"Fesoterodine is a muscarinic M3 receptor antagonist that relaxes bladder smooth muscle to reduce urinary incontinence and overactive bladder symptoms.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:12:27.413Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Overactive bladder with symptoms of urge incontinence, urgency, and frequency"}]},"trialDetails":[{"nctId":"NCT01557244","phase":"PHASE3","title":"A Study To Find Out How Fesoterodine Works In Children Aged 6 To 17 Years With Bladder Overactivity Caused By A Neurological Condition","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-07-02","conditions":"Urinary Bladder, Neurogenic","enrollment":181},{"nctId":"NCT02501928","phase":"PHASE3","title":"Open-label Long-term Extension Study of Fesoterodine in Japanese Subjects With Neurogenic Detrusor Overactivity.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2015-06-05","conditions":"Urinary Bladder, Neurogenic","enrollment":12}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Safety extension phase"],"phase":"phase_3","status":"active","brandName":"Fesoterodine PR","genericName":"Fesoterodine PR","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fesoterodine PR is a small molecule medication used to treat urinary bladder conditions, specifically those caused by a neurological condition. It is available in two doses, 4 mg and 8 mg, and has been compared to oxybutynin in clinical trials.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}